- Report
- February 2021
- 500 Pages
United States
From €2308EUR$2,400USD£1,980GBP
- Report
- July 2022
- 255 Pages
Global
From €3063EUR$3,185USD£2,627GBP
€4375EUR$4,550USD£3,753GBP
- Report
- October 2022
- 177 Pages
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- October 2022
- 174 Pages
North America
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- October 2022
- 202 Pages
Europe
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
India
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 90 Pages
France
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Russia
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Germany
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Canada
From €4567EUR$4,750USD£3,918GBP
Basaglar is a type of endocrine and metabolic disorder drug used to treat type 1 and type 2 diabetes. It is a long-acting insulin analog that helps to control blood sugar levels. It works by mimicking the action of natural insulin in the body, helping to reduce the amount of sugar in the blood. Basaglar is administered through an injection, either subcutaneously or intramuscularly. It is typically taken once a day, although the dosage may vary depending on the individual's needs.
Basaglar is a relatively new drug, having been approved by the FDA in 2014. It is marketed by Eli Lilly and Company, and is available in both the United States and Europe. Other companies that produce similar drugs include Novo Nordisk, Sanofi, and Merck. Basaglar is also available in generic form, with several generic manufacturers offering the drug. Show Less Read more